Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects

• Published in: Antimicrobial agents and chemotherapy Vol. 68; no. 6; p. e0156323
• Main Authors: Li, Size, Zhu, Xu, Cao, Guoying, Shen, Jufang, Yu, Jicheng, Wu, Xiaojie, Wu, Jufang, Yang, Haijing, Li, Nanyang, Hu, Yingying, Wang, Jingjing, Huang, Haihui, Zhang, Jing
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 05.06.2024
• Subjects: Adult; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacokinetics; Antimicrobial Chemotherapy; Area Under Curve; China; Double-Blind Method; East Asian People; Female; Half-Life; Healthy Volunteers; Humans; Male; Pharmacology; Polymyxins - adverse effects; Polymyxins - pharmacokinetics; Young Adult; China; pharmacokinetics; EVER206; SPR206; safety; polymyxins
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/aac.01563-23

EVER206 (also known as SPR206) is a novel polymyxin analog that has shown potency and efficacy against multidrug-resistant (MDR) Gram-negative pathogens. This randomized, double-blinded, placebo-controlled, Phase I study evaluated the safety, tolerability, and pharmacokinetics of EVER206 in healthy Chinese subjects. After single administration of 50-300 mg EVER206, the C ranged from 3.94 to 25.82 mg/L, and the AUC ranged from 12.42 to 101.67 h·mg/L. The plasma exposure displayed a linear relationship with the dose administered. After administration of 75 and 100 mg of EVER206 every 8 hours (q8 hour), a steady state was achieved on Day 2. The accumulation ratios of C and AUC from Day 1 to Day 7 were in the range of 1.12 to 1.3. The elimination half-lives ranged from 2.86 to 4.32 hours in the single-ascending-dose (SAD) study and 4.71 to 6.18 hours in the multiple-ascending-dose (MAD) study. The urinary excretion of unchanged EVER206 increased with the dose, with the mean cumulative fraction ranging from 23.70% to 47.10%. EVER206 was safe and well-tolerated in Chinese healthy subjects. No severe treatment emerging adverse events (TEAEs), serious adverse events, or TEAEs leading to discontinuation were reported. The results of the present study demonstrated a similar safety profile of EVER206 with data reported in an earlier study on SPR206-101. The exposure of EVER206 in Chinese healthy subjects was higher than that in Australian healthy subjects. These results could enable further clinical development of EVER206 in Chinese patients with severe MDR Gram-negative pathogen infections.CLINICAL TRIALSThis study was registered at the Chinese Clinical Trial Registry under identifier ChiCTR2200056692.